You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Neuroendocrine

Showing 1 - 25 of 2,013
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Pancreatic Adenocarcinoma, Adenosquamous Carcinoma, Pancreatic Neuroendocrine Tumor Trial (ESK981)

Not yet recruiting
  • Pancreatic Adenocarcinoma
  • +6 more
  • (no location specified)
Aug 4, 2023

Neuroendocrine Carcinomas, Neuroendocrine Tumors, Carcinoma, Neuroendocrine Trial run by the National Cancer Institute (NCI)

Not yet recruiting
  • Neuroendocrine Carcinomas
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Sep 22, 2023

Evaluation of Study Experiences of Neuroendocrine Tumor Patients

Not yet recruiting
  • Neuroendocrine Tumors
    • San Francisco, California
      Power Life Sciences
    Jul 21, 2023

    Neuroendocrine Tumors, Neuroendocrine Tumor of the Lung, Neuroendocrine Tumor Grade 1 Trial in Iowa City ([212Pb] VMT-a-NET,

    Recruiting
    • Neuroendocrine Tumors
    • +4 more
    • [212Pb] VMT-α-NET
    • [203Pb] VMT-α-NET SPECT/CT
    • Iowa City, Iowa
      Holden Comprehensive Cancer Center at the University of Iowa
    Nov 30, 2023

    Clinical Relevance of Salvage Treatment for Colorectal

    Completed
    • Rectal Neoplasms
    • Neuroendocrine Tumors
    • salvage treatment
    • (no location specified)
    Nov 16, 2023

    Development of New Personalised 3D Preclinical Models of

    Recruiting
    • Pancreatic Neuroendocrine Tumor
      • Milan, MI, Italy
        IRCCS San Raffele Institute
      Nov 2, 2023

      Gastrointestinal Neuroendocrine Carcinoma Trial in Beijing (Durvalumab and Chemotherapy(oxaliplatin and capecitabine))

      Recruiting
      • Gastrointestinal Neuroendocrine Carcinoma
      • Durvalumab and Chemotherapy(oxaliplatin and capecitabine)
      • Beijing, Beijing, China
        Peking Union Medical College Hospital
      Oct 1, 2023

      Neuroendocrine Tumors Trial in Hyderabad (Endoscopic submucosal dissection, EFTR)

      Recruiting
      • Neuroendocrine Tumors
      • Endoscopic submucosal dissection
      • EFTR
      • Hyderabad, Telangana, India
        Asian institute of Gastroenterology
      Nov 11, 2023

      Digestive System Neuroendocrine Tumor G1, Digestive System Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine

      Not yet recruiting
      • Digestive System Neuroendocrine Tumor G1
      • +5 more
      • Tumor Debulking
      • +5 more
      • Nashville, Tennessee
        Vanderbilt University/Ingram Cancer Center
      Aug 23, 2023

      Surufatinib in G3 Neuroendocrine Tumors

      Not yet recruiting
      • Neuroendocrine Tumor Grade 3
      • (no location specified)
      Aug 2, 2023

      Neuroendocrine Tumors, NET, Pancreatic Neuroendocrine Tumor Trial in Newport Beach, Denver, Dallas (nab-sirolimus)

      Not yet recruiting
      • Neuroendocrine Tumors
      • +4 more
      • Newport Beach, California
      • +2 more
      Aug 16, 2023

      Advanced Gastroenteropancreatic Neuroendocrine Tumor Trial (68Ga-DOTATOC)

      Not yet recruiting
      • Advanced Gastroenteropancreatic Neuroendocrine Tumor
      • (no location specified)
      Oct 16, 2023

      Neuroendocrine Tumors Trial (Lutathera)

      Not yet recruiting
      • Neuroendocrine Tumors
      • (no location specified)
      Aug 9, 2023

      Pancreatic Neuroendocrine Tumor G2 Trial (Octreotide LAR)

      Completed
      • Pancreatic Neuroendocrine Tumor G2
      • Octreotide LAR
      • (no location specified)
      Oct 17, 2023

      Surufatinib Plus Sintilimab Combined With Chemotherapy in

      Recruiting
      • Gastric Neuroendocrine Carcinoma
      • Tianjin, Tianjin, China
        Tianjin Medical University Cancer Institute and Hospital
      Oct 22, 2023

      Gastroenteropancreatic Neuroendocrine Tumours

      Recruiting
      • Gastroenteropancreatic Neuroendocrine Tumor
      • 68Ga-DOTATOC PET as a part of their clinical diagnostic work-up will be included
      • Milano, Italy
        Irccs San Raffaele
      Nov 24, 2023

      Neuroendocrine Tumors, Somatostatin Receptor-positive Neuroendocrine Tumor Trial in Madison (Single Photon Emission Computed

      Not yet recruiting
      • Neuroendocrine Tumors
      • Somatostatin Receptor-positive Neuroendocrine Tumor
      • Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT)
      • +3 more
      • Madison, Wisconsin
        University of Wisconsin - Madison
      Nov 2, 2023

      Large Cell Neuroendocrine Carcinoma of the Lung Trial in Athens (Atezolizumab, Carboplatin, Etoposide)

      Completed
      • Large Cell Neuroendocrine Carcinoma of the Lung
      • Athens, Greece
      • +1 more
      Sep 16, 2023

      Neuroendocrine Tumors, Well-Differentiated Neuroendocrine Carcinoma, High Grade Neuroendocrine Carcinoma, Any Site Trial in San

      Not yet recruiting
      • Neuroendocrine Tumors
      • +2 more
      • San Francisco, California
        University of California, San Francisco
      Feb 17, 2023

      Multi-dimensional Fragmentomic Assay for Early Detection of

      Not yet recruiting
      • Pancreatic Neuroendocrine Tumor
      • Fragmentomic profiles of plasma cfDNA
      • (no location specified)
      Apr 27, 2023

      GEP-NET, Neuroendocrine Tumors, Neuroendocrine Carcinoma Trial in Copenhagen (18F-FDG, 64Cu-Dotatate)

      Enrolling by invitation
      • GEP-NET
      • +3 more
      • Copenhagen, Denmark
        Rigshospitalet
      Jan 24, 2023

      Advanced Solid Tumors With Neuroendocrine Differentiation Trial (surufatinib?serplulimab)

      Not yet recruiting
      • Advanced Solid Tumors With Neuroendocrine Differentiation
      • (no location specified)
      Nov 27, 2023

      Neuroendocrine Neoplasms Including Adrenocortical Carcinoma

      Recruiting
      • Neuroendocrine Tumors
      • Carcinoma, Neuroendocrine
        • Bethesda, Maryland
          National Institutes of Health Clinical Center
        Jan 20, 2023

        Neuroendocrine Tumors Trial in Beijing (Surufatinib Combined With Temozolomide and S-1)

        Not yet recruiting
        • Neuroendocrine Tumors
        • Surufatinib Combined With Temozolomide and S-1
        • Beijing, Beijing, China
          Cancer Institute and Hospital, Chinese Academy of Medical Scienc
        Sep 8, 2023

        Small Cell Lung Cancer, Neuroendocrine Carcinoma Trial in Zhengzhou (ZG006)

        Not yet recruiting
        • Small Cell Lung Cancer
        • Neuroendocrine Carcinoma
        • ZG006
        • Zhengzhou, Henan, China
          Henan Cancer Hospital
        Aug 6, 2023